Phosphodiesterase-4 (PDE4) is an intracellular pro-inflammatory enzyme that is considered a therapeutic target in inflammatory disorders such as psoriasis, asthma or ulcerative colitis (UC), among others. Researchers from Palisade Bio Inc. have reported preclinical data on PALI-2108, a PDE4 inhibitor prodrug, in models of UC.
It has been previously demonstrated that genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes. Researchers from MD Anderson Cancer Center have now conducted work to assess the role of TXNRD1 in regulating tissue aging.
Applying chimeric antigen receptor (CAR) T-cell therapy to T-cell malignancies presents important limitations due to immune suppression caused by T-cell depletion, in addition to CAR T self-killing and CAR T transfection of malignant cells.
Exxel Pharma Inc. is advancing EX-937 for patients suffering from refractory chronic cough. EX-937 works by specifically inhibiting the fatty acid amide hydrolase (FAAH) enzyme, thereby increasing the levels of anandamide, a naturally occurring signaling molecule.
Genialis Inc. and Debiopharm SA have entered into an agreement to define and discover biomarkers within the DNA damage repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.
Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).
Researchers from Renmin Hospital of Wuhan University have published results from their work that aimed to assess the role of exonuclease 1 (EXO1) in the progression of prostate cancer (PCa). A series of bioinformatic analyses revealed that EXO1 expression was higher in PCa tissue compared to normal tissue, and that high EXO1 expression predicted poor prognosis in PCa patients.
When a cell is invaded by a virus, the cell triggers an innate immune response by activating retinoic acid-inducible gene I (RIG-I) like receptors (RLRs), among others, that are essential for controlling viral replication. Even though several ubiquitin ligases (E3) have been identified to positively or negatively regulate RLRs post-translationally, the E3 ligases directly involved in RLR transcription are still unknown. A screening including 375 ubiquitin E3 ligases identified E3 ubiquitin-protein ligase UBR5 as a positive regulator of RLR transcription.
Increasing evidence exists suggesting plasma exosomal microRNAs (miRNAs) are involved in tumor progression, but their role in breast cancer is still unknown. Plasma exosome miRNA sequencing revealed that elevated levels of miR-361-3p were significantly correlated with malignant breast cancer progression in patients.
RSS
